

Special Issue

Nutrient Sensing, Redox Homeostasis and Metabolic Diseases: Molecular Insight

Message from the Guest Editor

The dysfunction of the metabolic system generally occurs due to the disturbance in energy balance, nutrient sensing, and altered redox homeostasis, leading to the development of various disorders, including diabetes, obesity, and cancer. An intervention involving diet manipulation or caloric restriction have shown some promising outcomes, including a delay in age-related disease. Pathways that mainly involve energy sensing and homeostasis are mTOR, sirtuins (SIRT1), AMPK, and insulin/insulin growth factor-1 (IGF-1). Alteration in these pathways may lead to altered nutrient sensing and redox homeostasis and thus the development of metabolic disorders. Understanding the mechanism behind how these pathways are altered during the progression or development of metabolic diseases could be beneficial for managing these diseases. For this Special Issue, we invite articles related to the areas of cellular or systemic metabolism, nutrient sensing, redox homeostasis, drugs mimicking dietary intervention, or caloric restrictions such as metformin and resveratrol in metabolic diseases including obesity, diabetes, cardiovascular, liver disorders, and cancers.

Guest Editor

Dr. Bal Krishna Chaube

Vascular Biology & Therapeutics Section, Department of Comparative Medicine, Yale University School of Medicine, New Haven, CT 06520, USA

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/105753

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).